APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psychoactive Substances

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Psychoactive Substances Market Outlook and Growth Opportunities 2026

31 December 2025192 pages

Choose your research edition.

Industry ResearchPsychoactive Substances Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Psychoactive Substances Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Psychoactive Substances Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psychoactive Substances Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Psychoactive Substances Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Psychoactive Substances market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Psychoactive Substances is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Psychoactive Substances is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Psychoactive Substances is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Psychoactive Substances market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Psychoactive Substances market include Alpha-CAT, AusCann Group Holdings Pty Ltd., Cannabics Pharmaceuticals Inc., Cape Bouvard Technologies Pty Ltd, Cyrelian Pty Ltd., Enecta., GD Pharma, GW Pharmaceuticals PLC. and MedReleaf Australia, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Psychoactive Substances market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Psychoactive Substances and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Psychoactive Substances revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Psychoactive Substances market.

Psychoactive Substances Segment by Company

Alpha-CAT

AusCann Group Holdings Pty Ltd.

Cannabics Pharmaceuticals Inc.

Cape Bouvard Technologies Pty Ltd

Cyrelian Pty Ltd.

Enecta.

GD Pharma

GW Pharmaceuticals PLC.

MedReleaf Australia

Teewinot Life Sciences

Tilray

Zynerba Pharmaceuticals

Psychoactive Substances Segment by Type

Cannabinoids

Hallucinogens

Stimulants

Depressants

Psychoactive Substances Segment by Application

Neuropathic Disorders

Spasticity

Cancer

Psychoactive Substances Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Psychoactive Substances status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Psychoactive Substances key companies, revenue, market share, and recent developments.

3. To split the Psychoactive Substances breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Psychoactive Substances market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Psychoactive Substances significant trends, drivers, influence factors in global and regions.

6. To analyze Psychoactive Substances competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychoactive Substances market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psychoactive Substances and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychoactive Substances.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psychoactive Substances industry.

Chapter 3: Detailed analysis of Psychoactive Substances company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Psychoactive Substances in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Psychoactive Substances in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Psychoactive Substances Industry Trends Table 2. Psychoactive Substances Industry Drivers Table 3. Psychoactive Substances Industry Opportunities and Challenges Table 4. Psychoactive Substances Industry Restraints Table 5. Global Psychoactive Substances Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Psychoactive Substances Revenue Share by Company (2021-2026) Table 7. Global Psychoactive Substances Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Psychoactive Substances Key Company Manufacturing Base & Headquarters Table 9. Global Psychoactive Substances Company, Product Type & Application Table 10. Global Psychoactive Substances Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Psychoactive Substances by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cannabinoids Table 15. Significant Companies of Hallucinogens Table 16. Significant Companies of Stimulants Table 17. Significant Companies of Depressants Table 18. Global Psychoactive Substances Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Psychoactive Substances Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Psychoactive Substances Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Psychoactive Substances Sales Value Share by Type (2021-2026) Table 22. Global Psychoactive Substances Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Neuropathic Disorders Table 24. Significant Companies of Spasticity Table 25. Significant Companies of Cancer Table 26. Global Psychoactive Substances Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Psychoactive Substances Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Psychoactive Substances Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Psychoactive Substances Sales Value Share by Application (2021-2026) Table 30. Global Psychoactive Substances Sales Value Share by Application (2027-2032) Table 31. Global Psychoactive Substances Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Psychoactive Substances Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Psychoactive Substances Sales Value Share by Region (2021-2026) Table 34. Global Psychoactive Substances Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Psychoactive Substances Sales Value Share by Region (2027-2032) Table 36. Global Psychoactive Substances Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Psychoactive Substances Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Psychoactive Substances Sales Value Market Share by Country (2021-2026) Table 39. Global Psychoactive Substances Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Psychoactive Substances Sales Value Market Share by Country (2027-2032) Table 41. Alpha-CAT Company Information Table 42. Alpha-CAT Business Overview Table 43. Alpha-CAT Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Alpha-CAT Psychoactive Substances Product Portfolio Table 45. Alpha-CAT Recent Development Table 46. AusCann Group Holdings Pty Ltd. Company Information Table 47. AusCann Group Holdings Pty Ltd. Business Overview Table 48. AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio Table 50. AusCann Group Holdings Pty Ltd. Recent Development Table 51. Cannabics Pharmaceuticals Inc. Company Information Table 52. Cannabics Pharmaceuticals Inc. Business Overview Table 53. Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio Table 55. Cannabics Pharmaceuticals Inc. Recent Development Table 56. Cape Bouvard Technologies Pty Ltd Company Information Table 57. Cape Bouvard Technologies Pty Ltd Business Overview Table 58. Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio Table 60. Cape Bouvard Technologies Pty Ltd Recent Development Table 61. Cyrelian Pty Ltd. Company Information Table 62. Cyrelian Pty Ltd. Business Overview Table 63. Cyrelian Pty Ltd. Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio Table 65. Cyrelian Pty Ltd. Recent Development Table 66. Enecta. Company Information Table 67. Enecta. Business Overview Table 68. Enecta. Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Enecta. Psychoactive Substances Product Portfolio Table 70. Enecta. Recent Development Table 71. GD Pharma Company Information Table 72. GD Pharma Business Overview Table 73. GD Pharma Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. GD Pharma Psychoactive Substances Product Portfolio Table 75. GD Pharma Recent Development Table 76. GW Pharmaceuticals PLC. Company Information Table 77. GW Pharmaceuticals PLC. Business Overview Table 78. GW Pharmaceuticals PLC. Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio Table 80. GW Pharmaceuticals PLC. Recent Development Table 81. MedReleaf Australia Company Information Table 82. MedReleaf Australia Business Overview Table 83. MedReleaf Australia Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. MedReleaf Australia Psychoactive Substances Product Portfolio Table 85. MedReleaf Australia Recent Development Table 86. Teewinot Life Sciences Company Information Table 87. Teewinot Life Sciences Business Overview Table 88. Teewinot Life Sciences Psychoactive Substances Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Teewinot Life Sciences Psychoactive Substances Product Portfolio Table 90. Teewinot Life Sciences Recent Development Table 91. Tilray Company Information Table 92. Tilray Business Overview Table 93. Tilray Psychoactive Substances Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Tilray Psychoactive Substances Product Portfolio Table 95. Tilray Recent Development Table 96. Zynerba Pharmaceuticals Company Information Table 97. Zynerba Pharmaceuticals Business Overview Table 98. Zynerba Pharmaceuticals Psychoactive Substances Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio Table 100. Zynerba Pharmaceuticals Recent Development Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Psychoactive Substances Product Image Figure 2. Global Psychoactive Substances Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psychoactive Substances Market Size (2021-2032) & (US$ Million) Figure 4. Global Psychoactive Substances Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cannabinoids Image Figure 8. Hallucinogens Image Figure 9. Stimulants Image Figure 10. Depressants Image Figure 11. Global Psychoactive Substances Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Psychoactive Substances Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Psychoactive Substances Sales Value Share by Type (2021-2032) Figure 14. Neuropathic Disorders Image Figure 15. Spasticity Image Figure 16. Cancer Image Figure 17. Global Psychoactive Substances Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Psychoactive Substances Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Psychoactive Substances Sales Value Share by Application (2021-2032) Figure 20. Global Psychoactive Substances Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Psychoactive Substances Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Psychoactive Substances Sales Value (2021-2032) & (US$ Million) Figure 23. North America Psychoactive Substances Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Psychoactive Substances Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Psychoactive Substances Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Psychoactive Substances Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Psychoactive Substances Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Psychoactive Substances Sales Value (2021-2032) & (US$ Million) Figure 29. South America Psychoactive Substances Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Psychoactive Substances Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Psychoactive Substances Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Psychoactive Substances Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Psychoactive Substances Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Psychoactive Substances Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Cannabinoids
  • Hallucinogens
  • Stimulants
  • Depressants
Applications
  • Neuropathic Disorders
  • Spasticity
  • Cancer
Companies covered
  • Alpha-CAT
  • AusCann Group Holdings Pty Ltd.
  • Cannabics Pharmaceuticals Inc.
  • Cape Bouvard Technologies Pty Ltd
  • Cyrelian Pty Ltd.
  • Enecta.
  • GD Pharma
  • GW Pharmaceuticals PLC.
  • MedReleaf Australia
  • Teewinot Life Sciences
  • Tilray
  • Zynerba Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Psychoactive Substances Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Psychoactive Substances Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Psychoactive Substances Market Dynamics
  1. 2.1 Psychoactive Substances Industry Trends
  2. 2.2 Psychoactive Substances Industry Drivers
  3. 2.3 Psychoactive Substances Industry Opportunities and Challenges
  4. 2.4 Psychoactive Substances Industry Restraints
3 Psychoactive Substances Market by Company
  1. 3.1 Global Psychoactive Substances Company Revenue Ranking in 2025
  2. 3.2 Global Psychoactive Substances Revenue by Company (2021-2026)
  3. 3.3 Global Psychoactive Substances Company Ranking (2024-2026)
  4. 3.4 Global Psychoactive Substances Company Manufacturing Base and Headquarters
  5. 3.5 Global Psychoactive Substances Company Product Type and Application
  6. 3.6 Global Psychoactive Substances Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Psychoactive Substances Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Psychoactive Substances Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Psychoactive Substances Market by Type
  1. 4.1 Psychoactive Substances Type Introduction
  2. 4.1.1 Cannabinoids
  3. 4.1.2 Hallucinogens
  4. 4.1.3 Stimulants
  5. 4.1.4 Depressants
  6. 4.2 Global Psychoactive Substances Sales Value by Type
  7. 4.2.1 Global Psychoactive Substances Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Psychoactive Substances Sales Value by Type (2021-2032)
  9. 4.2.3 Global Psychoactive Substances Sales Value Share by Type (2021-2032)
5 Psychoactive Substances Market by Application
  1. 5.1 Psychoactive Substances Application Introduction
  2. 5.1.1 Neuropathic Disorders
  3. 5.1.2 Spasticity
  4. 5.1.3 Cancer
  5. 5.2 Global Psychoactive Substances Sales Value by Application
  6. 5.2.1 Global Psychoactive Substances Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Psychoactive Substances Sales Value by Application (2021-2032)
  8. 5.2.3 Global Psychoactive Substances Sales Value Share by Application (2021-2032)
6 Psychoactive Substances Regional Value Analysis
  1. 6.1 Global Psychoactive Substances Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Psychoactive Substances Sales Value by Region (2021-2032)
  3. 6.2.1 Global Psychoactive Substances Sales Value by Region: 2021-2026
  4. 6.2.2 Global Psychoactive Substances Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Psychoactive Substances Sales Value (2021-2032)
  7. 6.3.2 North America Psychoactive Substances Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Psychoactive Substances Sales Value (2021-2032)
  10. 6.4.2 Europe Psychoactive Substances Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Psychoactive Substances Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Psychoactive Substances Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Psychoactive Substances Sales Value (2021-2032)
  16. 6.6.2 South America Psychoactive Substances Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Psychoactive Substances Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Psychoactive Substances Sales Value Share by Country, 2025 VS 2032
7 Psychoactive Substances Country-level Value Analysis
  1. 7.1 Global Psychoactive Substances Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Psychoactive Substances Sales Value by Country (2021-2032)
  3. 7.2.1 Global Psychoactive Substances Sales Value by Country (2021-2026)
  4. 7.2.2 Global Psychoactive Substances Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Psychoactive Substances Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Psychoactive Substances Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Psychoactive Substances Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Psychoactive Substances Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Psychoactive Substances Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Psychoactive Substances Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Psychoactive Substances Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Psychoactive Substances Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Psychoactive Substances Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Psychoactive Substances Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Psychoactive Substances Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Psychoactive Substances Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Psychoactive Substances Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Psychoactive Substances Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Psychoactive Substances Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Psychoactive Substances Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Psychoactive Substances Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Psychoactive Substances Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Psychoactive Substances Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Psychoactive Substances Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Psychoactive Substances Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Psychoactive Substances Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Psychoactive Substances Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Psychoactive Substances Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Psychoactive Substances Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Psychoactive Substances Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Psychoactive Substances Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Psychoactive Substances Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Psychoactive Substances Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Psychoactive Substances Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alpha-CAT
  2. 8.1.1 Alpha-CAT Company Information
  3. 8.1.2 Alpha-CAT Business Overview
  4. 8.1.3 Alpha-CAT Psychoactive Substances Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alpha-CAT Psychoactive Substances Product Portfolio
  6. 8.1.5 Alpha-CAT Recent Developments
  7. 8.2 AusCann Group Holdings Pty Ltd.
  8. 8.2.1 AusCann Group Holdings Pty Ltd. Company Information
  9. 8.2.2 AusCann Group Holdings Pty Ltd. Business Overview
  10. 8.2.3 AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio
  12. 8.2.5 AusCann Group Holdings Pty Ltd. Recent Developments
  13. 8.3 Cannabics Pharmaceuticals Inc.
  14. 8.3.1 Cannabics Pharmaceuticals Inc. Company Information
  15. 8.3.2 Cannabics Pharmaceuticals Inc. Business Overview
  16. 8.3.3 Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio
  18. 8.3.5 Cannabics Pharmaceuticals Inc. Recent Developments
  19. 8.4 Cape Bouvard Technologies Pty Ltd
  20. 8.4.1 Cape Bouvard Technologies Pty Ltd Company Information
  21. 8.4.2 Cape Bouvard Technologies Pty Ltd Business Overview
  22. 8.4.3 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio
  24. 8.4.5 Cape Bouvard Technologies Pty Ltd Recent Developments
  25. 8.5 Cyrelian Pty Ltd.
  26. 8.5.1 Cyrelian Pty Ltd. Company Information
  27. 8.5.2 Cyrelian Pty Ltd. Business Overview
  28. 8.5.3 Cyrelian Pty Ltd. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio
  30. 8.5.5 Cyrelian Pty Ltd. Recent Developments
  31. 8.6 Enecta.
  32. 8.6.1 Enecta. Company Information
  33. 8.6.2 Enecta. Business Overview
  34. 8.6.3 Enecta. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Enecta. Psychoactive Substances Product Portfolio
  36. 8.6.5 Enecta. Recent Developments
  37. 8.7 GD Pharma
  38. 8.7.1 GD Pharma Company Information
  39. 8.7.2 GD Pharma Business Overview
  40. 8.7.3 GD Pharma Psychoactive Substances Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GD Pharma Psychoactive Substances Product Portfolio
  42. 8.7.5 GD Pharma Recent Developments
  43. 8.8 GW Pharmaceuticals PLC.
  44. 8.8.1 GW Pharmaceuticals PLC. Company Information
  45. 8.8.2 GW Pharmaceuticals PLC. Business Overview
  46. 8.8.3 GW Pharmaceuticals PLC. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio
  48. 8.8.5 GW Pharmaceuticals PLC. Recent Developments
  49. 8.9 MedReleaf Australia
  50. 8.9.1 MedReleaf Australia Company Information
  51. 8.9.2 MedReleaf Australia Business Overview
  52. 8.9.3 MedReleaf Australia Psychoactive Substances Revenue and Gross Margin (2021-2026)
  53. 8.9.4 MedReleaf Australia Psychoactive Substances Product Portfolio
  54. 8.9.5 MedReleaf Australia Recent Developments
  55. 8.10 Teewinot Life Sciences
  56. 8.10.1 Teewinot Life Sciences Company Information
  57. 8.10.2 Teewinot Life Sciences Business Overview
  58. 8.10.3 Teewinot Life Sciences Psychoactive Substances Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teewinot Life Sciences Psychoactive Substances Product Portfolio
  60. 8.10.5 Teewinot Life Sciences Recent Developments
  61. 8.11 Tilray
  62. 8.11.1 Tilray Company Information
  63. 8.11.2 Tilray Business Overview
  64. 8.11.3 Tilray Psychoactive Substances Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Tilray Psychoactive Substances Product Portfolio
  66. 8.11.5 Tilray Recent Developments
  67. 8.12 Zynerba Pharmaceuticals
  68. 8.12.1 Zynerba Pharmaceuticals Company Information
  69. 8.12.2 Zynerba Pharmaceuticals Business Overview
  70. 8.12.3 Zynerba Pharmaceuticals Psychoactive Substances Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio
  72. 8.12.5 Zynerba Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst